- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01748214
Premature Infant Exposure to Noise Generated by Respiratory Support
Infants in neonatal intensive care units are increasing exposed to non-invasive ventilatory support modes (nasal continuous positive airway pressure - NCPAP and high flow nasal cannula: >1 L/min flow - HFNC). While there have been small descriptive studies of noise exposure in infants on NCPAP, there have been no comparative trials done comparing noise exposure in infants undergoing both NCPAP and HFNC.
Objective: Using a cross-over model determine noise exposure levels in infants exposed to similar levels of respiratory support provided by NCPAP and HFNC.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University Of Virginia Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Premature infant born < 32 weeks and 0 days post-conceptional age;
- Seven or more days of age and not in acute respiratory distress;
- Need for nasal continuous positive airway pressure or high-flow nasal cannula for ventilation or supplemental oxygen delivery;
- In a neutral-thermal environment (i.e. isolette)
Exclusion Criteria:
- Oro-facial congenital anomalies;
- Congenital heart disease (except for patent ductus arteriosus and/or patent foramen ovale);
- Unstable respiratory status as deemed by the attending physician
- Patients under isolation for infectious disease
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Nasal CPAP
Infants received nasal CPAP as standard of care.
|
High Flow Nasal Cannual
Infants received high flow nasal cannula as standard of care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Noise level
Time Frame: 6 days
|
Noise levels will be measured during a set time while infants are on Nasal CPAP and Nasal High flow cannula as standard of care
|
6 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Joshua Attridge, MD, UVA School of Medicine
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13164
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Premature Birth of Newborn
-
Children's National Research InstitutePatient-Centered Outcomes Research InstituteCompletedPremature Birth of Newborn | Newborn Morbidity | Family | Immature Newborn | Infant Newborn DiseaseUnited States
-
Shaare Zedek Medical CenterTerminatedPremature Birth of NewbornIsrael
-
Case Western Reserve UniversityCompleted
-
University of California, San FranciscoUniversity of California, San Diego; University of California, Los Angeles; Kaiser...CompletedPremature Birth of NewbornUnited States
-
Universitaire Ziekenhuizen KU LeuvenKU LeuvenUnknownPremature Birth of NewbornBelgium
-
Universidad Complutense de MadridCompletedPremature Birth of Newborn
-
Washington University School of MedicineUniversity of Southern CaliforniaCompletedPremature Birth of NewbornUnited States
-
Vestre Viken Hospital TrustHaukeland University HospitalActive, not recruiting
-
University of ArkansasCompletedPremature Birth of NewbornUnited States
-
Elgan Pharma Ltd.Terminated